

616.37
T 61

Editors:

DANIEL TIMOFTE AKE ANDREN-SANDBERG

PANCREATIC CANCER AN EVERLASTING SURGICAL CHALLENGE

„Gr. T. Popa” Publisher, U.M.F. Iași

616.34

T 61

**Daniel Timofte
Ake Andrén-Sandberg**

Pancreatic cancer - an everlasting surgical challenge

756600

Universitatea de Stat de
Medicină și Farmacie
„Nicolae Testemițanu”

Biblioteca Științifică Medicină

sl.3



**„Gr. T. Popa” Publisher, U.M.F. Iași
2018**

CONTENTS

1. Pancreatic Carcinogenesis.....	10
1.1. Precursor Lesions of Pancreatic Cancer.....	12
1.2. Tumour Suppressor Genes	12
2. Screening for Pancreatic Cancer Why, How, and Who	17
2.1. The Investigation of Pancreatic Cancer	17
2.2. How Can Screening Benefit Be Evaluated in Common Cancers?.....	19
2.3. What problems can arise related to the accuracy of screening tests?....	20
2.4. How Can Individuals Be Identified by Taking into Consideration the Risk Factors?	21
2.5. Which are the Clinical and Genetic Risk Factors for Pancreatic Cancer?.....	22
2.6. Challenges in Creating an Effective Screening Test.....	23
2.6.1. Actual Serum Biomarkers	23
2.6.2. Prospects for Novel Biomarkers.....	24
2.7. How Can Imaging Be Used in Screening?.....	25
2.8. Identification of High Risk Premalignant Lesions: PanINs and IPMNs	26
2.9. Initial Clinical Studies of Screening in Pancreatic Cancer	27
2.10.Early Detection Could Increase Survival at Many Patients	27
2.11.The Future of Screening for Pancreatic Cancer	27
2.12.Which Could Be the Opportunities for Prevention?	28
3. Molecular Signatures of Pancreatic Cancer	29
3.1. Genetics of Precursor Lesions.....	29
3.2. Genetics of Histologic Variants of Pancreatic Cancer	30
3.3. Epigenetics of Pancreatic Cancer	32
3.4. Oncogenes	32

3.5. Genome Maintenance Genes.....	36
3.6. Growth Factors.....	37
3.7. Telomere Shortening	38
3.7.1. DNA Methylation.....	39
3.7.2. Aberrant Hypermethylation in Pancreatic Cancer.....	39
3.7.3. Aberrant Methylation in Precursor Lesions	41
3.7.4. Aberrant Hypomethylation in Pancreatic Cancer.....	42
3.8. Molecular Biomarkers and Therapy.....	45
3.9. Future Perspectives	47
4. Endoscopic ultrasonography for surveillance of individuals at high risk for pancreatic cancer	48
4.1. Precursor Lesions	48
4.1.1. Pancreatic intraepithelial neoplasia	48
4.1.2. Mucinous cystic neoplasms.....	48
4.1.3. Intraductal papillary mucinous neoplasms	49
4.2. Role of Endoscopic Ultrasonography	49
4.3. Cost Effectiveness	55
4.4. Future Perspectives	57
5. Update on Familial Pancreatic Cancer	60
5.1. Using Family History to Assess Cancer Risk.....	61
5.2. Family History and Extrapancreatic Malignancies	62
5.3. Intraductal Papillary Mucinous Neoplasms and Extrapancreatic Neoplasms	63
5.4. Familial Pancreatic Cancer Genes	63
5.5. Therapeutic Implications	63
5.6. Prophylactic Surgery in Patients with Familial Pancreatitis	64
5.7. Screening for Early.....	64

6. Crosstalk of Sp1 and Stat3 signalling in pancreatic cancer pathogenesis	66
6.1. Molecular pathogenesis of pancreatic cancer.....	66
6.2. Sp1 and pancreatic cancer biology	67
6.3. Roles of Sp1 in pancreatic tumour angiogenesis.....	68
6.4. Roles of Sp1 in pancreatic cancer metastasis	69
6.5. Sp1 expression in, and prognosis and targeted therapy for pancreatic cancer	71
6.6. Stat3 and pancreatic cancer biology	72
6.7. Roles of Stat3 in pancreatic cancer proliferation	72
6.8. Roles of Stat3 in pancreatic tumour angiogenesis.....	74
6.9. Roles of Stat3 in pancreatic cancer metastasis	76
6.10. Modulation of Stat3 functions for therapeutic for pancreatic cancer	77
6.11. Tyrosine kinase inhibitors	77
6.12. Stat3-targeting RNAi.....	79
6.13. Small-molecule compounds	80
6.14. Other therapies.....	81
6.15. Sp1 and Stat3 crosstalk in pancreatic cancer cells	81
6.16. Interactions between Sp1 and Stat3.....	81
6.17. Modulation of both Sp1 and Stat3 function for therapy for pancreatic cancer	84
6.18. Conclusions and future directions	85
7. Recent Progress in Pancreatic Cancer	88
7.1. Solid Tumors	93
7.2. Cystic Neoplasms	97
7.3. Signs and Symptoms	98
7.4. Clinical Staging	100

8.	Therapeutic options for the management of pancreatic cancer	107
8.1.	Diagnosis.....	108
8.2.	Current development in Pancreatic Cancer	110
8.3.	Localized Disease: Stage I/II and Stage III Borderline Resectable	110
8.4.	Patient choosing for operation.....	111
8.5.	Surgery for Localized disease	112
9.	Trends in the resection of the distal pancreas	113
10.	Whipple Made Simple for Surgical Pathologists	117
10.1.	Other Pertinent Structures Presented Externally: Portal Vein	117
10.2.	Opening and Sectioning	117
10.2.1.	Opening the Duodenum; Examining Intraduodenal Pathology	117
10.2.2.	Dissection of the LNs (by the Orange-peeling Method)	119
10.2.3.	Sectioning of the Pancreas, Ducts, and Ampulla	121
10.2.4.	Probing of CBD and pancreatic duct.....	122
10.2.5.	Bivalving the pancreatic head along the probes	122
10.2.6.	Evaluation of the bivalved specimen and further dissection ...	124
10.3.	Macroscopic Clues to the Tumour Recognition	126
10.4.	Microscopic Verification; Considerations.....	128
10.5.	Laparoscopy / Laparotomy	128
10.5.1.	Distal Pancreatectomy.....	128
10.5.2.	Minimally Invasive Surgery	130
10.6.	Surgical Complications	131
10.7.	Effects of the Operation	131
10.8.	Pancreaticoduodenectomy or Pancreaticogastroduodenectomy or “Whipple” Contents of the Specimen	131
10.9.	Terminology Issues	136
10.10.	Orientation and Identification of Important Structures in the Gross Roo	
		139

10.11. Further Surrogate Clues to Orientation	142
10.12. Dissection and Sampling	143
10.13. External Examination and Obtaining Margins	143
10.13.1. Examination of the Specimen Externally	143
10.14. Optional Superficial Sampling of a Palpable Tumour for Banking .	144
10.15. Removal of the Margins and Surfaces.....	144
10.16. Adjuvant Therapy.....	146
10.17. Neo-adjuvant Therapy for Localized Disease	148
10.18. The Debate over Radiation Therapy.....	149
11. Recent Progress in Pancreatic Cancer.....	152
11.1. Novel adjuvant therapy methods	152
11.2. Locally Advanced Pancreatic Adenocarcinoma.....	152
11.3. Therapeutic Resistance in Pancreatic Cancer.....	155
11.3.1. Cellular mechanisms of therapeutic resistance	155
11.3.2. Extracellular mechanisms of therapeutic resistance	158
11.4 Future Perspectives.....	160
11.4.1 Pancreatic cancer cells	161
11.4.2 Pancreatic cancer stem cells.....	162
11.4.3 Tumour microenvironment	163
11.4.4 Metabolic pathways	165
11.5 Metastatic disease treatment.....	166
11.6 Forthcoming therapies	169
12. Pain Evaluation and Therapy	171
12.1. Depression	174
12.2. End of Life.....	174
13. The Significance of Multidisciplinary Care	176
13.1. Risk factors.....	176

13.2. Diabetes and pancreatic cancer mechanisms of risk	177
13.3. Diabetes mellitus and pancreatic cancer	178
13.4. Is long-lasting diabetes mellitus a moderate risk factor for carcinoma of the pancreas?	179
13.5. Incipient diabetes in carcinoma of the pancreas concludes with resection of carcinoma	188
13.6. What is a possible approach to screen for carcinoma of the pancreas in incipient diabetes?	192
13.7. Chronic Pancreatitis (Cp) As a Danger Factor for Pdac	198
13.7.1. The Function of Stellate Cellular Activation in PDAC	199
13.7.2. Function of CCK in PDAC Evolution	199
13.7.3. Diabetes as a Danger Factor for Pdac	200
14. Pancreatogenic (TYPE 3c) Diabetes	203
15. Genomic Connexions of CP, DM, AND PDAC	208
15.1. Techniques of action of incretins	214
15.2. Findings of a human pancreatic biobank research	215
References	225